Terms: = Ovarian cancer AND SMAD4, JIP, Q13485, 4089, ENSG00000141646, MADH4, DPC4
90 results:
1. A cellular model provides insights into the pathogenicity of the oncogenic FOXL2 somatic variant p.Cys134Trp.
Herman L; Amo A; Legois B; Di Carlo C; Veitia RA; Todeschini AL
Br J Cancer; 2024 May; 130(9):1453-1462. PubMed ID: 38429437
[TBL] [Abstract] [Full Text] [Related]
2. The miR-33a-5p/CROT axis mediates ovarian cancer cell behaviors and chemoresistance
Li X; Gao X; Yuan J; Wang F; Xu X; Wang C; Liu H; Guan W; Zhang J; Xu G
Front Endocrinol (Lausanne); 2022; 13():950345. PubMed ID: 36120434
[TBL] [Abstract] [Full Text] [Related]
3. Clinico-genomic Characterization of ATM and HRD in Pancreas cancer: Application for Practice.
Park W; O'Connor CA; Bandlamudi C; Forman D; Chou JF; Umeda S; Reyngold M; Varghese AM; Keane F; Balogun F; Yu KH; Kelsen DP; Crane C; Capanu M; Iacobuzio-Donahue C; O'Reilly EM
Clin Cancer Res; 2022 Nov; 28(21):4782-4792. PubMed ID: 36040493
[TBL] [Abstract] [Full Text] [Related]
4. MicroRNA miR-30a inhibits cisplatin resistance in ovarian cancer cells through autophagy.
Cai Y; An B; Yao D; Zhou H; Zhu J
Bioengineered; 2021 Dec; 12(2):10713-10722. PubMed ID: 34747309
[TBL] [Abstract] [Full Text] [Related]
5. Abnormal methylation characteristics predict chemoresistance and poor prognosis in advanced high-grade serous ovarian cancer.
Feng LY; Yan BB; Huang YZ; Li L
Clin Epigenetics; 2021 Jul; 13(1):141. PubMed ID: 34289901
[TBL] [Abstract] [Full Text] [Related]
6. LncRNA PVT1 promotes the progression of ovarian cancer by activating TGF-β pathway via miR-148a-3p/AGO1 axis.
Wu Y; Gu W; Han X; Jin Z
J Cell Mol Med; 2021 Sep; 25(17):8229-8243. PubMed ID: 34288373
[TBL] [Abstract] [Full Text] [Related]
7. A novel homeostatic loop of sorcin drives paclitaxel-resistance and malignant progression via smad4/ZEB1/miR-142-5p in human ovarian cancer.
Zhang J; Guan W; Xu X; Wang F; Li X; Xu G
Oncogene; 2021 Jul; 40(30):4906-4918. PubMed ID: 34163033
[TBL] [Abstract] [Full Text] [Related]
8. TP53 variant allele frequency correlates with the chemotherapy response score in ovarian/fallopian tube/peritoneal high-grade serous carcinoma.
Lawson BC; Yang RK; Euscher ED; Ramalingam P; Malpica A
Hum Pathol; 2021 Sep; 115():76-83. PubMed ID: 34153306
[TBL] [Abstract] [Full Text] [Related]
9. GPBAR1 Promotes Proliferation of Serous ovarian cancer by Inducing smad4 Ubiquitination.
Li H; Zhao J; Shi X
Appl Immunohistochem Mol Morphol; 2021 Aug; 29(7):519-526. PubMed ID: 33605573
[TBL] [Abstract] [Full Text] [Related]
10. Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast cancer or ovarian cancer, 2012-2019.
Kurian AW; Ward KC; Abrahamse P; Bondarenko I; Hamilton AS; Deapen D; Morrow M; Berek JS; Hofer TP; Katz SJ
J Clin Oncol; 2021 May; 39(15):1631-1640. PubMed ID: 33560870
[TBL] [Abstract] [Full Text] [Related]
11. Immunohistochemical Loss of dpc4 in Tumors With Mucinous Differentiation Arising in or Involving the Gynecologic Tract.
Kwon DH; Malpica A; Zaleski M; Euscher ED; Ramalingam P
Int J Gynecol Pathol; 2021 Nov; 40(6):523-532. PubMed ID: 33405429
[TBL] [Abstract] [Full Text] [Related]
12. CircATRNL1 activates smad4 signaling to inhibit angiogenesis and ovarian cancer metastasis via miR-378.
Wang J; Li Y; Zhou JH; Shen FR; Shi X; Chen YG
Mol Oncol; 2021 Apr; 15(4):1217-1233. PubMed ID: 33372356
[TBL] [Abstract] [Full Text] [Related]
13. Epithelial-mesenchymal transition polarization in ovarian carcinomas from patients with high social isolation.
Lutgendorf SK; Penedo F; Goodheart MJ; Dahmoush L; Arevalo JMG; Thaker PH; Slavich GM; Sood AK; Cole SW
Cancer; 2020 Oct; 126(19):4407-4413. PubMed ID: 32691853
[TBL] [Abstract] [Full Text] [Related]
14. Mutant FOXL2
Weis-Banke SE; Lerdrup M; Kleine-Kohlbrecher D; Mohammad F; Sidoli S; Jensen ON; Yanase T; Nakamura T; Iwase A; Stylianou A; Abu-Rustum NR; Aghajanian C; Soslow R; Da Cruz Paula A; Koche RP; Weigelt B; Christensen J; Helin K; Cloos PAC
Cancer Res; 2020 Sep; 80(17):3466-3479. PubMed ID: 32641411
[TBL] [Abstract] [Full Text] [Related]
15. MicroRNA-145-5p regulates the proliferation of epithelial ovarian cancer cells via targeting smad4.
Zhou J; Zhang X; Li W; Chen Y
J Ovarian Res; 2020 May; 13(1):54. PubMed ID: 32366274
[TBL] [Abstract] [Full Text] [Related]
16. smad4 induces cell death in HO-8910 and SKOV3 ovarian carcinoma cell lines via PI3K-mTOR involvement.
Yao Y; Zhang Z; Kong F; Mao Z; Niu Z; Li C; Chen A
Exp Biol Med (Maywood); 2020 May; 245(9):777-784. PubMed ID: 32276544
[TBL] [Abstract] [Full Text] [Related]
17. Inhibiting of self-renewal, migration and invasion of ovarian cancer stem cells by blocking TGF-β pathway.
Wen H; Qian M; He J; Li M; Yu Q; Leng Z
PLoS One; 2020; 15(3):e0230230. PubMed ID: 32214328
[TBL] [Abstract] [Full Text] [Related]
18. A comparison of disease recurrence between robotic versus laparotomy approach in patients with intermediate-risk endometrial cancer.
Song J; Le T; Hopkins L; Fung-Kee-Fung M; Lupe K; Gaudet M; E C; Samant R
Int J Gynecol Cancer; 2020 Feb; 30(2):160-166. PubMed ID: 31871112
[TBL] [Abstract] [Full Text] [Related]
19. A FXYD5/TGF‑β/SMAD positive feedback loop drives epithelial‑to‑mesenchymal transition and promotes tumor growth and metastasis in ovarian cancer.
Bai Y; Li LD; Li J; Chen RF; Yu HL; Sun HF; Wang JY; Lu X
Int J Oncol; 2020 Jan; 56(1):301-314. PubMed ID: 31746425
[TBL] [Abstract] [Full Text] [Related]
20. Expression of smad4 is Retained in Most Gynecologic Tumors with Mucinous Differentiation.
Alghamdi S; Alghaashamy K; Pinto A
Int J Gynecol Pathol; 2020 Sep; 39(5):493-497. PubMed ID: 31569186
[TBL] [Abstract] [Full Text] [Related]
[Next]
